← All indications
Bronchitis, Chronic
A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.
Drugs by status
Approved for this indication (41)
- roflumilast
- levofloxacin
- fluticasone
- aclidinium
- arformoterol
- theophylline
- cefdinir
- cefixime
- ceftibuten
- cefditoren
- dirithromycin
- salmeterol
- gemifloxacin
- glycopyrronium
- umeclidinium
- ipratropium
- formoterol
- sulfamethoxazole
- telithromycin
- indacaterol
- ciprofloxacin
- azithromycin
- budesonide
- clarithromycin
- tiotropium
- cefuroxime
- vilanterol
- moxifloxacin
- dyphylline
- cefaclor
- +11 more
Phase 4 trials (9)
Phase 3 trials (3)
Phase 2 trials (9)
Organizations
Organization Involved with Phase 4 Indications (23)
- Merck
- Sanofi
- Zambon
- CPL Associates
- NeuTec Pharma
- Qingfeng Pharmaceutical Group
- Sunovion
- bene-Arzneimittel GmbH
- Ahn-Gook Pharmaceuticals Co.,Ltd
- The Netherlands Asthma Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- Johns Hopkins University
- Radboud University
- University of Milan
- Nanchang University
- University of British Columbia
- University of California, Los Angeles
- Medaimun GmbH
- Catholic University of Korea
- University of Sao Paulo
- State University of New York, Buffalo
- University of Alabama, Birmingham
- Dutch Health Care Insurance Board
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (12)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (7)